US-based medical device company, Mela Sciences has signed an expanded three-year manufacturing agreement with its long-term supplier, Askion, to manufacture MelaFind handheld device.

MelaFind is a non-invasive, objective automated point of care system that aids dermatologist to obtain additional information to help decide whether to biopsy certain indeterminate pigmented skin lesions.

Mela Sciences president and CEO Joseph V. Gulfo said the extended agreement enables a secure supply of MelaFind handheld devices for the next three years.

The company intends to launch MelaFind in US and the European Union, initially in Germany, in the first quarter of this year.

Mela Sciences is focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.